Jump to content
  • RQA Membership - only £25 for the rest of 2018

    Includes all membership benefits.

    Click now to join us
  • A great place to network

    2018 Annual Conference, Manchester Central, 31 Oct - 2 Nov.

    View Programme

Key facts

The number of new RQA members who join the Association each year. We currently have just over 2200 members.

The number of Committee Members in 2018, these volunteers help with everything from new booklets to conference organisation.

The Association is forty years old.

Who are RQA

The Research Quality Association (RQA) is a professional membership body dedicated to informing and advancing its members. We provide status and visibility for individuals engaged in the quality of research concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since our inception in 1977, the Association has increased and evolved to reflect regulatory changes, the growing impact of regulatory inspection and the ever-changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research.  

Read more+

Our Mission

1. To develop and promote quality standards in scientific research.

2. To facilitate knowledge sharing and transfer through:

  • Discussion
  • Training
  • Seminars
  • Forums 
  • Conferences
  • Publications
  • Podcasts
  • Partnership and co-operation

3. To liaise with regulatory agencies in the development and interpretation of regulations and guidance.

Newsletter

Sign up to the latest news and events.

Latest News

View all news

Medical Devices FDA News

Quality in 510(k) 'Quik' Review Programme Pilot The FDA has launched the Quality in 510(k) ('Quik') Review Programme pilot. The goal of this pilot is to simplify how manufacturers of certain moderate risk medical devices complete a premarket notification (510(k)) submission, and to evaluate whether use of the FDA’s free eSubmitter software will result in well-organised submissions that can be reviewed more efficiently.

Read more+

Brexit: EMA updates information for holders of centralised marketing authorisations

According to the European Medicines Agency (EMA), marketing authorisation holders (MAHs), applicants and sponsors of centrally authorised medicines for human or veterinary use should consider how Brexit will impact their medicines and which changes need to be addressed before the UK leaves the EU. They also need to ensure that the necessary changes are made by that date.

Read more+

Brexit - UK Government update on implementation period

The British Government has issued technical information on what the implementation period means for the life science sector. This includes details on how the EU’s new Clinical Trials Regulation (CTR) will be approached by the UK.

Read more+